A Developmental Perspective on Paragangliar Tumorigenesis

Lavinia Vittoria Lotti 1, Simone Vespa 2,3, Mattia Russel Pantalone 4, Silvia Perconti 2,3, Diana Liberata Esposito 2,3, Rosa Visone 2,3, Angelo Veronese 5, Mario Sanna 7, Fabio Verginelli 8, Cecilia Soderberg Naucler 4 and Renato Mariani-Costantini 2,3,*

1 Department of Experimental Medicine, “La Sapienza” University, Viale Regina Elena 324, 00161 Rome, Italy; laviniavittoria.lotti@uniroma1.it
2 Center of Sciences on Aging and Translational Medicine (CeSI-MeT), “G. d’Annunzio” University, Via Luigi Polacchi 11, 66100 Chieti, Italy; sv85@libero.it (S.V.); percontisilvia@gmail.com (S.P.); d.esposito@unich.it (D.L.E); r.visone@unich.it (R.V.)
3 Department of Medical, Oral and Biotechnological Sciences, “G. d’Annunzio” University, Via dei Vestini 31, 66100 Chieti, Italy
4 Department of Medicine (Solna), Division of Microbial Pathogenesis, BioClinicum, Karolinska Institutet, 17164 Stockholm, Sweden; mattia.pantalone@ki.se (M.R.P.); cecilia.naucler@ki.se (C.S.N.)
5 Department of Medicine and Aging Sciences, “G. d’Annunzio” University, Via Luigi Polacchi 11, 66100 Chieti, Italy; a.veronese@unich.it
6 Department of Oncology-Hematology, Service of Anatomic Pathology, “Guglielmo da Saliceto” Hospital, Via Taverna 49, 29121 Piacenza, Italy; carlopaties@yahoo.it
7 Skull Base Unit, “Gruppo Otologico” Piacenza-Roma, Via Antonio Emmanueli, 42, 29121 Piacenza, Italy; mario.sanna@gruppootologico.it
8 Department of Pharmacy, “G. d’Annunzio” University, Via dei Vestini 31, 66100 Chieti, Italy; verginelli@unich.it
* Correspondence: rmc@unich.it

Received: 30 January 2019; Accepted: 21 February 2019; Published: 26 February 2019

Abstract: In this review, we propose that paraganglioma is a fundamentally organized, albeit aberrant, tissue composed of neoplastic vascular and neural cell types that share a common origin from a multipotent mesenchymal-like stem/progenitor cell. This view is consistent with the pseudohypoxic footprint implicated in the molecular pathogenesis of the disease, is in harmony with the neural crest origin of the paraganglia, and is strongly supported by the physiological model of carotid body hyperplasia. Our immunomorphological and molecular studies of head and neck paragangliomas demonstrate in all cases relationships between the vascular and the neural tumor compartments, that share mesenchymal and immature vasculo-neuronal markers, conserved in derived cell cultures. This immature, multipotent phenotype is supported by constitutive amplification of NOTCH signaling genes and by loss of the microRNA-200s and -34s, which control NOTCH1, ZEB1, and PDGFRA in head and neck paraganglioma cells. Importantly, the neuroepithelial component is distinguished by extreme mitochondrial alterations, associated with collapse of the ∆Ψm. Finally, our xenograft models of head and neck paraganglioma demonstrate that mesenchymal-like cells first give rise to a vasculo-angiogenic network, and then self-organize into neuroepithelial-like clusters, a process inhibited by treatment with imatinib.

Keywords: carotid body; angiogenesis; mitochondria; neural crest; neurogenesis; paraganglioma; stem-like tumor cells; vasculogenesis; xenograft
1. Introduction

1.1. Intersections between Tumorigenesis, Histogenesis, and Tissue Regeneration

Tumors are capable of autonomous and aberrant growth, but, as normal tissues, can grow only after achieving a structural organization, which requires the coordinated contribution of different cell types, the establishment of appropriate cell–cell and cell–matrix interactions and the development of specific scaffolds and vascular networks [1]. However, much of the basic information about the structural and functional organization of neoplastic tissues is still lacking. For instance, the key question of whether tumors contain cells able to transdifferentiate into both vascular and parenchymal cell types is still debated [2]. We do not know to what extent tumors follow the histogenetic blueprint of their normal tissue counterparts, and we do not fully understand which of the several tumor-resident cell types can regenerate neoplastic tissue after damage inflicted by therapy [3–6]. Nonetheless, it is clear that evolutionarily conserved developmental programs and signaling pathways intersect tumorigenesis, histo/organogenesis, and tissue repair/regeneration [1,6]. In particular, invasive and/or metastatic tumors essentially imitate the organogenetic program of the neural crest, a transient embryonic structure that characterizes the evolution of procraniates and craniates (Cristozoa) [7].

The temporary neural crest milieu defines a highly plastic population of migratory and multipotent cells that, in response to complex signals—including morphogen gradients, cell–cell interactions, availability of oxygen and nutrients, and topography—dedifferentiate via the epithelial–mesenchymal transition (EMT) program, migrate, proliferate, and again re-differentiate via the reverse mesenchymal–epithelial transition (MET) program, giving rise to an amazing variety of cell types and tissues throughout the axial body region [4,8]. While the embryonic population of neural crest cells is ephemeral, it appears that in postnatal tissues and organs the perivascular niche preserves multipotent stem/progenitor-like cells that retain tissue-specific histogenetic instructions that are reactivated during regeneration and repair [4,9–12]. Such cells might link development, tissue regeneration, and neoplasia.

1.2. Paragangliomas and Pheochromocytomas

Paragangliomas (PGLs) are rare, generally sluggish but invasive and potentially lethal tumors arising from the neural crest-derived paraxial autonomic ganglia (paraganglia) of parasym pathetic (mainly head and neck) or sympat hodrenal (mainly truncal) lineage [13]. Pheochromocytomas are in essence catecholamine-producing tumors that arise mainly from the chromaffin cells of the adrenal medulla, also of neural crest origin, and present with a constellation of symptoms secondary to catecholamine overload, eventually leading to severe cardiovascular disorders and death [14]. It is estimated that 10–20% of all pheochromocytomas and PGLs (collectively termed PPGLs) manifest a malignant behavior, in terms of synchronous or metachronous metastatic spread, generally associated with poor prognosis [15]. Metastatic progression seems less common in head and neck PGLs (HNPGL, ≈5%) and pheochromocytomas (≈10%) than in thoraco-abdominal PGLs (15% to 35%) [15–17]. However, despite intensive research, no clinicopathological, molecular, or genetic criteria that unequivocally distinguish PPGLs with metastatic potential have been identified [15–18]. Therefore, to overcome diagnostic problems, the WHO Endocrine Tumor Classification recently acknowledged metastatic potential to all PPGLs [19,20]. This implies life-long follow-up after surgery for all cases and additional risk stratification according to pathological, clinical, biochemical, and genetic evidence [17,21].

Collectively, PPGLs may provide important insights into the intersection(s) between organogenesis and tumorigenesis, as it is plainly evident that their basically conserved histostructure mimics that shared by their normal tissue counterparts, the extramedullary paraganglia and the adrenal medulla. In fact, as exemplified in Figure 1, PPGL tissue quite invariably consists in nests or ribbons of more or less dysplastic neurosecretory cells, fairly circumscribed and “nursed” by glial cells, with the whole resting on a highly vascular framework composed of dysplastic endothelia and pericytes that may assume frankly angiomatos features [22]. Thus, PPGLs provide a model for
“organoid” tumors, i.e., tumors consisting of a tridimensional assemblage of cells of more than one type, arranged to form predictable tissue-like structures mimicking those of the organ of origin.

Intriguingly, PPGLs are among the tumors most frequently associated with autosomal dominant genetic predisposition, found in up to ≈40% of the cases [23–25]. The genes most commonly involved are those encoding the four subunits of the succinate dehydrogenase (SDH) enzyme, namely SDHA, SDHB, SDHC, and SDHD, and the SDH assembly co-factor, i.e., SDHAF2. Furthermore, PPGLs
have been associated with germline mutations in other genes, including RET, NF1, VHL, EPNAS1, FH, MDH2, EGLN1/2, TMEM127, and MAX, some of which are linked to hereditary neoplastic syndromes including other neural crest tumors, such as multiple endocrine neoplasia (RET), von-Hippel-Lindau syndrome (VHL), neurofibromatosis type 1 (NF1), and Carney-Stratakis syndrome (SDH genes) [23–25]. Notably, a maternal parent-of-origin effect, interpreted as evidence for “imprinting,” is implicated in the transmission of SDHD, SDHAF2, and MAX mutations [26]. Regardless of this effect, which may result in generation skipping, the penetrance of the mutations in the SDH genes that are most commonly associated with PPGL is surprisingly low; in fact, it has been reliably estimated at only 1.7% for SDHA, 22.0% for SDHB, and 8.3% for SDHC [27]. Furthermore, mice mutated in sdhb, the human SDHB homolog, do not develop any type of cancer [28]. All this suggests that germline SDH mutations predispose to PPGL, but are not sufficient for tumorigenesis. The environmental and/or constitutional factors that might modulate hereditary PPGL risk and contribute to PPGL, even in the absence of genetic predisposition, are currently unknown, with the exception, for carotid body PGL, of exposure to chronic hypoxia, such as in people living at high altitudes or in patients affected with chronic obstructive pulmonary disease or cyanotic heart defects [29–32].

Importantly, the most relevant genes implicated in PPGL predisposition, namely the SDH genes and VHL, as well as EPNAS1, FH, MDH2, and EGLN1/2, link PPGL tumorigenesis to pseudohypoxia, a cellular phenotype characterized by the constitutive expression of proteins involved in the adaptive responses to low partial pressures of oxygen [23–25]. Among other pleiotropic effects on metabolism, the EMT, vasculoangiogenesis, etc., pseudohypoxia deregulates growth factor signaling and attenuates cell death, promoting the expansion of immature cell populations [33]. The same processes, induced to various extents by chronic environmental hypoxia, are implicated in the adaptive growth of the carotid body, the paraganglion at the basis of the homeostatic oxygen-sensing system. Notably, the carotid body is the most frequent site of origin of head and neck PGL (HN) [34].

2. The Physiological Model of Carotid Body Hyperplasia Under Chronic Hypoxia May Illuminate Paraganglioma Development

Carotid body development has been recently delineated in a notable series of elegant studies from Ricardo Pardal’s group [35–37]. The carotid body is implicated in the organismal adaptation to chronic hypoxia, as in people living at high altitudes or in patients with cardiorespiratory diseases, in which cases, this organelle sustains marked hyperplasia and hypertrophy, reflecting the combined expansion of the neural and vascular tissue components, as in PGL. Pardal’s lab has clearly shown that this adaptive process is made possible via hypoxia inducible factor (HIF)-dependent reactivation of neural crest-derived resident stem-like cells retaining mesectodermal differentiation potential [36,37]. Such cells, overlooked because of lack of distinctive markers, remain quiescent under normoxia, but, under low partial pressure of oxygen, acquire a nestin+/GFAP- stem/progenitor cell phenotype and convert not only into new sustentacular and neuroepithelial cells, but also into endothelial and pericytic/mural cells, thus contributing to the impressive vasculoangiogenesis that sustains the hyperplastic carotid body. This capability of vasculo/neural transdifferentiation is consistent with the fact that both the neural ganglia of the autonomic nervous system and the cardiovascular structures of the upper trunk originate from the cephalic neural crest during embryogenesis [36]. Furthermore, it has been shown that stem-like neural cells can convert into vascular cells in vitro, and that neoplastic stem-like cells from neural tumors, such as glioblastoma, can give rise to tumor-derived endothelia in immunodeficient mice. This process, defined as vasculogenic mimicry, rather than being aberrant, might reflect the conservation of a physiological developmental potential, which is probably useful for tissue repair/regeneration [2,37–39].

Despite functional differences and the fact that they originate from distinct axial levels of the neural crest, the carotid body and the adrenal medulla are very much alike in tissue structure and cell types, and this similarity is maintained in the derived tumors. Furthermore, as demonstrated in several mammals, including humans, the adrenal medulla is also hypoxia-sensitive, particularly
in the neonatal period of life [40]. All this suggests that the developmental and genetic pathways responsible for the growth and homeostasis of the carotid body and of the adrenal medulla could be very similar. In support of this hypothesis, studies based on genetic cell fate tracing and on genetic ablation of Schwann cell precursors in avian and mammalian models revealed that the adrenal medulla originates from neural crest-derived multipotent precursors with a glial phenotype (“Schwann cell precursors”), that migrate along the developing sympathetic nerve to the adrenal area to differentiate into postsynaptic neuroendocrine chromaffin cells [41,42]. Surprisingly, the conclusions of these publications, highly relevant to our understanding of PGL and pheochromocytoma, have yet to be incorporated into the mainstream pathological and molecular interpretation of PPGL tumorigenesis.

In fact, it is currently assumed that the phenotypic plasticity of PPGL cells is circumscribed within the neuroepithelial lineage, a theory backed by the neuroepithelial-specific loss of SDHB protein in the SDH-related PPGLs, which conforms to the widely accepted two-hit hypothesis of tumor suppressor genes [43–46]. This would imply that a uniquely neoplastic neuroepithelial cell population drives PPGL growth stimulating angiogenesis and gliogenesis from adjacent normal blood vessels and nerves. Thus, the vascular (endothelial and pericytic) and the glial (sustentacular) PPGL components are relegated to ancillary roles. Such a view is incongruent with the hypothesis that PPGL tumorigenesis could aberrantly recapitulate the histogenesis of the carotid body and of the adrenal medulla [47,48]. Thus, the origin(s) and the nature of PPGL remain undefined and controversial.

3. Molecular Heterogeneities Do Not Exclude a Developmental Model of Paragangliar Tumorigenesis

PPGLs have been linked to germline and/or somatic mutations in more than 20 genes considered tumor-initiators and/or -drivers [23–25]. PPGL tissues bear the distinguishable molecular signatures of these gene mutations, and, on such a basis, can be subdivided into at least three major molecular clusters [49]. The first and largest cluster, identified by pseudohypoxic signaling, is related to loss-of-function mutations that stabilize HIFα, either indirectly, via metabolic inhibition of the α-ketoglutarate-dependent dioxygenases, as in the case of mutations in the Krebs cycle genes encoding the SDH enzyme subunits (SDHA/B/C/D), the SDH assembly factor (SDHAF2), fumarate hydratase (FH) and malate dehydrogenase 2 (MDH2); or directly, via disruption of HIFα proteasomal targeting, as in the case of VHL and of the genes encoding the prolyl hydroxylases 1 and 2 (EGLN1/2). Additionally, gain-of-function mutations in EPAS1, encoding HIF2α, contribute to this cluster. Functionally, the pseudohypoxic cluster is characterized by steady HIFα signaling, even under normoxia, and by a cascade of downstream effects, including a metabolic shift towards glycolysis, impaired oxidative phosphorylation, production of reactive oxygen species, DNA and histone hypermethylation, inhibition of collagen maturation and activation of the EMT, which is the widely recognized driver of the migratory mesenchymal-like cell phenotype and of vasculoangiogenesis [50].

With the exception of the VHL-related PPGLs, frequently located in the adrenals, the pseudohypoxic cluster encompasses mainly noradrenergic extra-adrenal PGLs and is clinically important because it includes the SDHB/FH-related PGLs associated with higher metastatic potential and higher risk of disease multiplicity/recurrence [51]. The second cluster, designated the kinase signaling cluster, bears the molecular signature of aberrant PI3K/AKT and RAS/MAPK activation. Tumors in this cluster are mainly pheochromocytomas and have mutations in various genes involved in protein kinase signaling networks, including NF1, KIF1B, MAX, RET, TMEM127, H-RAS, ATRX, and, more rarely, K-RAS and FGFR [52]. PPGL-associated fusion genes involving NGFR, BRAF, or NFI also contribute to this group. Although lacking the central pseudohypoxic footprint, the kinase signaling cluster relies on a glycolytic and glutaminolytic switch, necessary for cell proliferation and survival, as well as for chromatin remodeling. Clinically, the PPGLs in this cluster do not display a particularly aggressive behavior, except those associated with ATRX mutations [52]. Finally, the third cluster, also mainly adrenal, designated the Wnt signaling cluster, is associated with mutations in the cold shock domain containing E1 (CSDE1) gene and with fusion genes involving
the mastermind-like transcriptional coactivator 3 (MAML3). The PPGLs in this cluster tend to be hypomethylated and overexpress genes of the Wnt and Hedgehog pathways, known to play key roles in development [25]. Thus, the genomic landscape of PPGLs demonstrates clinically-relevant heterogeneity, but it is not granted that the distinctive molecular phenotypes entail substantial divergence in fundamental processes responsible for PPGL tissue development and growth. In fact, the molecular pathways defining the three major PPGL clusters are interrelated and participate in developmental processes [53–55]. Indeed, the relative uniformity of the organoid tissue organization of PPGLs suggests that different mutational backgrounds and molecular phenotypes converge on encouraging the aberrant activation of a single, pre-determined morphogenetic program that most likely retraces the developmental footsteps of paragangliar hyperplasia, as in the physiological model of the carotid body [37,56]. Furthermore, molecular phenotypes reflect microenvironmental interactions, which in complex tissues that contain cells of more than one type, like PPGLs, are likely modulated by the composition of the resident cell populations [57,58]. In this regard, PPGLs remain essentially faithful to their characteristic vasculo-neural architecture, but the extent to which the various vascular and neural cell types are represented in individual tumors, and their levels of differentiation, are variable [22,56]. Thus, the PPGL molecular clusters might reflect microenvironmental footprints, rather than differences in fundamental biological programs.

4. Ultrastructural and Immunomorphological Relationships Between the Vascular and Neural Compartments of Head and Neck Paragangiomas

In the past decade, we have tried to understand the relationships between the diverse PPGL cell types and to devise ways to capture the processes underlying PPGL development. Based on the characteristics of our patients, recruited at a skull base surgery center, we focused on HNPGLs, which mostly arise at the carotid bifurcation, in or around the jugular bulb, in the cervical tract of the vagus, or within the temporal bone. HNPGLs cause important morbidity and, when inoperable, are inevitably lethal [59].

We proceeded through sequential steps including: (1) analysis of the ultrastructural and immunomorphological relationships between the various resident HNPGL cell types; (2) identification of genes and molecular pathways common to HNPGLs; (3) localization of relevant protein products at the cellular and subcellular levels; (4) development and characterization of in vitro and in vivo models of HNPGL; and (5) use of such models, in conjunction with information derived from the preceding steps, to investigate HNPGL tissue development and evaluate the potential of specifically-targeted therapy [22,56]. None of the HNPGL cases recruited in our studies revealed evidence of metastasis, therefore our focus is on the reconstruction of the fundamental natural history of the disease, and not on factors linked to metastatic potential.

Using standard immunohistochemistry, classical electron microscopy (EM), and frozen section immunofluorescence (Figure 1), we confirmed that the endothelial, pericytic, glial, and neuroepithelial PGL cell types were clearly discriminated by specific markers (e.g., CD34, CD31, β2-microglobulin for endothelial cells; smooth muscle actin, S100, and GFAP for sustentacular cells; and chromogranin A and β3-tubulin for neuroepithelial cells). However, we also found that these allegedly distinct HNPGL cells coexpressed, to variable extents, markers associated with pluripotent mesenchymal stem-like state, vasculo/neurogenesis, and hypoxia (e.g., vimentin, nestin, CD44/HCAM, KIT/CD117, HIF2A, GLUT4, ZEB1, NOTCH1, DLK1, PDGFRA, VEGFR1/2) [22,56]. This was in agreement with flow cytometry, which highlighted within freshly-dissociated HNPGLs cell populations positive for stem-like mesenchymal cell markers (e.g., CD44/HCAM, CD73, CD90, CD105, and CD133). Further, the cells sorted for CD34 included subsets positive for stem (CD133, CD44/HCAM), neural (NCAM), or glial (GFAP) cell markers, suggesting pluripotency. A pluripotent potential was also consistent with the strong positivity of the endothelia for CD34, a sialomucin also expressed in mesenchymal progenitors and in gastrointestinal stromal tumors (GISTs), which co-occur with PGL in some SDH-related PGL syndromes [46,60], and for β2-microglobulin, a major histocompatibility complex
(MHC) class I component associated with infection, the EMT, and cancer [61]. Furthermore, EM, that we extensively utilized, revealed aberrant features in the contiguous vascular (endothelial/pericytic) and neural (glial/neuroepithelial) HNPGL compartments [56], and highlighted widespread contacts between the pervasive dendritic processes of the sustentacular cells and the plasma membranes of the neuroepithelial cells, suggesting contact-mediated sustentacular nurturing [22]. Most notably, at the ultrastructural level, the HNPGL cell types demonstrated a gradient in mitochondrial alterations, limited to occasional swelling of the cristae in the endothelial, pericytic, and sustentacular cells, but striking in the neuroepithelial cells, where the mitochondria were massively increased in number, extremely swollen, and presented convoluted or disrupted cristae [56]. Additionally, the mitochondria tended to form tight perinuclear clustering, a subcellular redistribution connected to an oxidant-rich nuclear microenvironment that promotes hypoxia-induced transcription [62]. These aberrant mitochondria appeared to be incompatible with normal respiration. In fact, the mitochondrial membrane potential ($\Delta \Psi_m$) collapsed in the neuroepithelial PGL component relative to autologous normal adipose tissue, while the $\Delta \Psi_m$ was only slightly decreased in the vascular component. This lineage-related pattern of mitochondrial alterations was found in all the HNPGLs analyzed, both mutated and unmutated in the SDH genes. However, larger mitochondria were significantly associated with the HNPGLs from SDHB/C/D gene mutation carriers [56].

5. Our Approach to the Study of Genes and Pathways Shared Among Head and Neck Paragangliomas

Back in 2013, we used high-density genome-wide copy number variation (CNV) analysis to identify HNPGL-related genes and pathways [22]. This analysis, then conducted on a pilot series of 24 tumors, including SDH-related and unrelated cases, versus matched blood, revealed in all cases a high level of chromosomal instability. A group of 104 genes, then mostly new to PPGL, was significantly over-represented among those affected by CNVs. We confirmed with orthogonal assays some of the most frequently amplified hits, including IDUA (4p16.3), NOTCH1 (9q34.3), JAG2 (14q32), HES5 (1p36.32), DVL1 (1p36), and CTBP1 (4p16) [22]. Interestingly, IDUA, whose loss-of-function mutations are linked to type 1 mucopolysaccharidosis, a lysosomal storage disease (LSD) [63], showed the highest concordance for CN gains ($p = 0.000002$ by Fisher’s exact test). Notably, the HNPGL-derived IDUA gene sequences did not show mutations. By frozen section immunofluorescence, alpha-L-iduronidase, the IDUA-encoded enzyme, was strongly expressed in the neuroepithelial component of all tested PGLs, including cases not amplified at the IDUA locus (Figure 2) [22]. Alpha-L-iduronidase is necessary for the lysosomal hydrolysis of iduronic acid-containing glycosaminoglycans, such as dermatan sulfate and heparan sulfate, important microenvironmental cofactors of cell behavior in development and cancer, that act as receptors for viruses, exosomes, lipoproteins, and growth factors and control Fibroblast Growth Factor (FGF) and Sonic Hedgehog signaling [64–66]. While the above reported functions may be relevant to tumorigenesis, the link between IDUA and PGL can be better understood considering that mucopolysaccharidosis type 1 is associated with the accumulation of morpho-functionally altered mitochondria in neural cells, an alteration ascribed to impaired mitophagy due to alpha-L-iduronidase deficiency [67]. In fact, in carriers of loss-of-function IDUA mutations, mitochondrial clearance is compromised, leading to the intraneuronal accumulation of pathological mitochondria, characterized by low $\Delta \Psi_m$ and swelling, loss of cristae, and vacuolation [67]. Contrariwise, in HNPGLs, alpha-L-iduronidase expression is high and the IDUA gene is unmutated [22], which suggests that the accumulation of dysfunctional mitochondria is due to primary factors and not to deficient clearance [56]. Indeed, high alpha-L-iduronidase expression might reflect upregulation of the mitophagic machinery, in response to the large and dysfunctional mitochondrial pool [68], a hypothesis supported by the frequent ultrastructural evidence of mitophagy in HNPGL neuroepithelial cells and by positivity of the mitochondria for LC3 and sequestosome (Figure 2).
6. Constitutive Notch Signaling in Head and Neck Paraganglioma

Bioinformatics analyses of tumor-derived gene databases are inherently biased toward better known pathways, which may divert attention from novelty. Nonetheless, it was notable that in our 2013 genome-wide CNV analysis of HNPGLs, “Notch signaling” stood out as the pathway with the highest statistical significance [22]. This pathway controls stem cell maintenance and binary cell fate specification in the vascular and parenchymal compartments, and directly affects nuclear and mitochondrial functions [69–71].

6. Constitutive Notch Signaling in Head and Neck Paraganglioma

Bioinformatics analyses of tumor-derived gene databases are inherently biased toward better known pathways, which may divert attention from novelty. Nonetheless, it was notable that in our 2013 genome-wide CNV analysis of HNPGLs, “Notch signaling” stood out as the pathway with the highest statistical significance [22]. This pathway controls stem cell maintenance and binary cell fate specification in the vascular and parenchymal compartments, and directly affects nuclear and mitochondrial functions [69–71].

The statistical emergence of Notch signaling rested on five Notch signaling-related genes targeted by recurrent amplifications [22]. These included NOTCH1, prototype of the NOTCH receptor family, JAG2, a NOTCH ligand linked to vasculogenesis and the EMT, HES5, a NOTCH1-activated transcriptional repressor involved in neural stem cells induction [72,73], DVL1, hub of the interactions between Notch and Wnt signaling [74], and CTBP1, a transcription regulator sensitive to the reduced form of nicotinamide-adenine dinucleotide (NADH), that in melanoma cells links NOTCH signaling to the drop of the intracellular NAD+ : NADH ratio caused by aerobic glycolysis [75,76]. NOTCH1 signaling is mediated by the NOTCH1 intracellular domain (NICD1), released by proteolysis of transmembrane NOTCH1 after ligand-induced activation, which relocates to the mitochondria and to the nucleus. In the mitochondria NICD1 inhibits BAX and deregulates complex I, an effect that could contribute to explain the deregulation of complex I activity reported in the SDH-mutated PGLs [77,78]. In the nucleus, NICD1 forms a transcriptional regulatory complex with Suppressor of Hairless and Mastermind, which prevents the expression of cell differentiation factors and mediates the HIFA-induced metabolic changes resulting in the Warburg effect [79,80]. Importantly, NOTCH and HIFA signaling are linked in a positive loop: hypoxia promotes NOTCH activation, and NOTCH signaling upregulates HIF2A, the driver of the pseudo-hypoxic phenotype [81]. As investigated using immunohistochemistry, immunofluorescence, and cryo-immuno-EM (Figure 3), the protein products of the top-amplified NOTCH1-related genes were highly expressed in all the PGLs analyzed, independently of CNV status at the respective loci and of presence or absence of germline SDHx mutations [22]. However, for some of these proteins, the levels and the subcellular localizations of the immunostaining varied with cell type. JAG2 was mainly expressed in the sustentacular cells, including their dendritic processes, which establish multiple contacts with the neuroepithelial cells [22]. Membrane NOTCH1 was strongest in the endothelial and sustentacular cells, while mitochondrial and nuclear NOTCH1 was more conspicuous in the neuroepithelial component, where the mitochondria...
are severely altered and contiguous to the nuclear envelope (Figure 3), suggesting a mitochondrial role in the nuclear delivery of NICD1 [22,56].

**Figure 3.** Notch pathway proteins in head and neck paraganglioma. (a) Semithin paraganglioma frozen section stained using immunofluorescence with an antibody that recognizes both membrane NOTCH1 and its active intracellular domain, NICD1 (green). In neuroepithelial cells, labeling is mainly concentrated in discrete cytoplasmic spots, suggesting mitochondrial localizations of NICD1. The adjacent endothelia (arrowheads) mainly reveal cell membrane NOTCH1 labeling (bar = 10 µm). (b) Immunohistochemical staining for the NOTCH ligand JAG2 is intense at the periphery of the neuroepithelial cell clusters, a typical location of the sustentacular cells (standard avidin-biotin immunoperoxidase counterstained with hematoxylin and eosin, bar = 10 µm). (c) Double immunofluorescence on semithin paraganglioma frozen section highlights punctate CTBP1 nuclear labeling in most cells. Red labeling identifies cells staining positive for vimentin, a mesenchymal marker (double immunofluorescence on semithin frozen section, bar = 10 µm). (d) Punctate membrane staining pattern (red) of the atypical NOTCH ligand DLK1 in paraganglioma cells (immunofluorescence on semithin frozen section, bar = 10 µm). (e) Electron micrograph of a neuroepithelial (“chief”) paraganglioma cell showing the accumulation of swollen mitochondria with disrupted cristae (M) next to the envelope of the nucleus (N) (bar = 1 µm). (f) Immunoelectron microscopic view of a similar ultrastructural field, showing dense NICD1 labeling of the perinuclear mitochondria with gold particles (ultrathin frozen section immunoelectronmicroscopy, bar = 1 µm).